$HALB Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases
https://www.accesswire.com/678515/halberd-mov...e-diseases
Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid
JACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation (OTC Pink:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Halberd also successfully replicated its previous successful elimination of each of the inflammatory cytokines listed as complete in the table below. Interleukin-2 is a pro-inflammatory cytokine whose role in Alzheimer's Disease is not very well established, particularly given the multiplicity of bio factors implicated in this devastating disease. It may cause neurodegeneration as well as provide neuroprotection, depending on the level. Maintaining the appropriate level of IL-2, and other inflammatory cytokines in CSF is critical to neuro-health.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "The ability to precisely control the exact level of IL-2 in cerebrospinal fluid may be another important step in halting the progression of Alzheimer's Disease; especially when this ability is combined with the precise control of the concentrations of phosphorylated- Tau, beta-Amyloid and other contributing inflammatory cytokines."
William A. Hartman, Halberd Corporation's Chairman, President & CEO, added, "The significance of these test results is that Halberd's technology can be used to precisely control the levels of inflammatory cytokines and neurotransmitters to inhibit progression, and aid in the treatment, of various neurodegenerative diseases, such as Alzheimer's, Lou Gehrig's Disease, PTSD, CTE and epilepsy, among others. No other approach gives this kind of precise control which is imperative in maintaining a healthy balance of needed elements in the body.
Hartman continued, "This tool has the potential to revolutionize medicine and the treatment of various neurologic and non-neurologic diseases and conditions. The potential of this as an effective treatment for Alzheimer's, PTSD and CTE is a huge step forward for medicine. Additionally, since Alzheimer's Disease shares a number of common inflammatory cytokines with several other diseases, such as cancer, this could lead to an effective treatment for those other diseases which also have eluded removal of the basic causes of the disease."
https://www.accesswire.com/678515/halberd-mov...e-diseases
Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid
JACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation (OTC Pink:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Halberd also successfully replicated its previous successful elimination of each of the inflammatory cytokines listed as complete in the table below. Interleukin-2 is a pro-inflammatory cytokine whose role in Alzheimer's Disease is not very well established, particularly given the multiplicity of bio factors implicated in this devastating disease. It may cause neurodegeneration as well as provide neuroprotection, depending on the level. Maintaining the appropriate level of IL-2, and other inflammatory cytokines in CSF is critical to neuro-health.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "The ability to precisely control the exact level of IL-2 in cerebrospinal fluid may be another important step in halting the progression of Alzheimer's Disease; especially when this ability is combined with the precise control of the concentrations of phosphorylated- Tau, beta-Amyloid and other contributing inflammatory cytokines."
William A. Hartman, Halberd Corporation's Chairman, President & CEO, added, "The significance of these test results is that Halberd's technology can be used to precisely control the levels of inflammatory cytokines and neurotransmitters to inhibit progression, and aid in the treatment, of various neurodegenerative diseases, such as Alzheimer's, Lou Gehrig's Disease, PTSD, CTE and epilepsy, among others. No other approach gives this kind of precise control which is imperative in maintaining a healthy balance of needed elements in the body.
Hartman continued, "This tool has the potential to revolutionize medicine and the treatment of various neurologic and non-neurologic diseases and conditions. The potential of this as an effective treatment for Alzheimer's, PTSD and CTE is a huge step forward for medicine. Additionally, since Alzheimer's Disease shares a number of common inflammatory cytokines with several other diseases, such as cancer, this could lead to an effective treatment for those other diseases which also have eluded removal of the basic causes of the disease."
